Your browser doesn't support javascript.
loading
A multi-omics analysis reveals CLSPN is associated with prognosis, immune microenvironment and drug resistance in cancers.
Chen, Yihong; Wen, Haicheng; Li, Yin; Han, Ying; Tan, Jun; Guo, Cao; Cai, Changjing; Liu, Ping; Peng, Yinghui; Liu, Yihan; Wang, Xinwen; Zeng, Shan; Feng, Ziyang; Shen, Hong.
Afiliación
  • Chen Y; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Wen H; Department of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Li Y; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Han Y; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Tan J; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Guo C; Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Cai C; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Liu P; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Peng Y; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Liu Y; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Wang X; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Zeng S; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Feng Z; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
  • Shen H; Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.
Biol Proced Online ; 25(1): 16, 2023 Jun 03.
Article en En | MEDLINE | ID: mdl-37268895
BACKGROUND: Immunotherapy is effective only in limited patients. It is urgent to discover a novel biomarker to predict immune cells infiltration status and immunotherapy response of different cancers. CLSPN has been reported to play a pivotal role in various biological processes. However, a comprehensive analysis of CLSPN in cancers has not been conducted. METHODS: To show the whole picture of CLSPN in cancers, a pan-cancer analysis was conducted in 9125 tumor samples across 33 cancer types by integrating transcriptomic, epigenomic and pharmacogenomics data. Moreover, the role of CLSPN in cancer was validated by CCK-8, EDU, colony formation and flow cytometry in vitro and tumor cell derived xenograft model in vivo. RESULTS: CLSPN expression was generally upregulated in most cancer types and was significantly associated with prognosis in different tumor samples. Moreover, elevated CLSPN expression was closely correlated with immune cells infiltration, TMB (tumor mutational burden), MSI (microsatellite instability), MMR (mismatch repair), DNA methylation and stemness score across 33 cancer types. Enrichment analysis of functional genes revealed that CLSPN participated in the regulation of numerous signaling pathways involved in cell cycle and inflammatory response. The expression of CLSPN in LUAD patients were further analyzed at the single-cell level. Knockdown CLSPN significantly inhibited cancer cell proliferation and cell cycle related cyclin-dependent kinase (CDK) family and Cyclin family expression in LUAD (lung adenocarcinoma) both in vitro and in vivo experiments. Finally, we conducted structure-based virtual screening by modelling the structure of CHK1 kinase domain and Claspin phosphopeptide complex. The top five hit compounds were screened and validated by molecular docking and Connectivity Map (CMap) analysis. CONCLUSION: Our multi-omics analysis offers a systematic understanding of the roles of CLSPN in pan-cancer and provides a potential target for future cancer treatment.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Biol Proced Online Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Biol Proced Online Año: 2023 Tipo del documento: Article País de afiliación: China